Skip to main content

Table 2 Comparison of parameters related to disease activity, quality of life and concomitant therapy between C3 and C4 cohorts at the 6-month and 12-month visit

From: Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry

 

6 months

12 months

C3 (n = 124)

C4 (n = 491)

p value

C3 (n = 124)

C4 (n = 491)

p value

DAS28-ESR (0–10)

5.4 (4.6–6.3)

4.0 (3.5–4.5)

< 0.001

3.7 (2.6–4.7)

3.7 (3.0–4.4)

0.710

TJC (28 joints)

9.0 (4.0–14.0)

3.0 (2.0–5.0)

< 0.001

3.0 (1.0–7.0)

2.0 (1.0–5.0)

0.490

SJC (28 joints)

6.0 (2.0–9.5)

2.0 (1.0–4.0)

< 0.001

2.0 (0.0–4.0)

2.0 (0.0–3.0)

0.498

ESR (mm/h)

28.0 (16.5–46.5)

22.0 (13.0–33.0)

< 0.001

16.5 (6.5–32.0)

19.0 (11.0–30.5)

0.052

CRP (mg/l)

15.0 (7.9–28.9)

5.7 (2.5–13.7)

< 0.001

4.7 (1.6–17.0)

5.0 (2.3–11.3)

0.766

SDAI (0–86)

30.2 (19.7–39.5)

13.9 (10.7–18.3)

< 0.001

13.8 (8.0–20.9)

11.3 (7.7–17.4)

0.093

PTGA (0–100)

61.0 (50.0–75.0)

40.0 (26.0–50.0)

< 0.001

36.0 (25.0–60.0)

33.0 (20.0–50.0)

0.044

MDGA (0–100)

58.0 (40.0–70.0)

30.0 (20.0–40.0)

< 0.001

25.0 (15.0–45.0)

25.0 (15.0–40.0)

0.812

HAQ-DI (0–3)

1.5 (1.1–1.9)

1.3 (0.9–1.6)

< 0.001

1.3 (0.9–1.9)

1.3 (0.9–1.6)

0.140

EQ-5D (− 0.59–1)

0.2 (0.1–0.7)

0.7 (0.5–0.7)

< 0.001

0.6 (0.1–0.7)

0.7 (0.5–0.8)

0.017

Concomitant csDMARDs

98 (79.0%)

414 (84.3%)

0.159

94 (75.8%)

407 (82.9%)

0.070

Concomitant MTX

79 (63.7%)

341 (69.5%)

0.220

77 (62.1%)

332 (67.6%)

0.245

Concomitant GCs

95 (76.6%)

374 (76.2%)

0.918

92 (74.2%)

370 (75.4%)

0.789

  1. Continuous variables are described through the median (interquartile range); categorical variables are characterised by n (%)
  2. DAS28-ESR 28-joint disease activity score with ESR, TJC tender joint count, SJC swollen joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SDAI Simplified Disease Activity Index, PTGA patient general assessment of disease activity, MDGA physician general assessment of disease activity, HAQ-DI Health Assessment Questionnaire, EQ-5D EuroQol 5 Dimension for measuring the quality of life, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, MTX methotrexate, GCs glucocorticoids
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us